Acetylsalicylic acid as an adjuvant therapy for schizophrenia.

Acetylsalicylic acid as an adjuvant therapy for shizophrenia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22886

Enrollment

Registered

2004-12-22

Start date

2004-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Acetylsalicylacid 1000mg vs Placebo for 3 months (All daily pantoprazol 40 mg).

Eligibility

Inclusion criteria

Inclusion criteria: 1. Schizophrenia 2. Schizo-affective disorder 3. Schizofreniform disorder according to DSM-IV (for max 10 years) 4. Age 18 - 55 years 5. Stabile, min. 60 on PANSS, min 2x a score of min 4 on PANSS.

Exclusion criteria

Exclusion criteria: 1. No contraindication for acetylsalicylic acid 2. No hypersensitivity to acetylsalicylic acid or pantoprazole 3. No significant somatic illness 4. No chronic use of a nonsteroidal anti-inflammatory drug (NSAID) 5. No use of corticosteroids 5. Not pregnant 6. No drugs dependency 7. Informed consent obtained.

Design outcomes

Primary

Measure	Time frame
3-month change in positive and negative symptoms on the total PANSS score.	—

Secondary

Measure	Time frame
3-month change in the PANSS subscales, cognitive symptoms, immunological parameters (g-interferon, IL-4, IL-6 and IL-12).	—

Contacts

Public ContactH. Burger

University Medical Center Groningen (UMCG), Department of Epidemiology and Bioinformatics P.O. Box 30.001

H.Burger@rug.nl

Outcome results